Damora Therapeutics, Inc. (DMRA): auditor change — Damora Therapeutics dismisses EY Denmark auditor, appoints EY US

Damora Therapeutics, Inc.

Audit Committee dismissed EY Denmark on April 17, 2026; EY US appointed same day.
No disagreements or reportable events occurred in FY 2024 or 2025 or the subsequent interim period.
EY Denmark's 2024 report included a going-concern explanatory paragraph.
Company provided EY Denmark with disclosures; EY Denmark's letter to SEC filed as Exhibit 16.1.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 1.0

Damora Therapeutics, Inc. dismissed EY Godkendt Revisionspartnerselskab as its auditor.

Action: dismissal
Auditor: EY Godkendt Revisionspartnerselskab

Exact text from the filing

On April 17, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), dismissed EY Godkendt Revisionspartnerselskab (“EY Denmark”) as the Company’s independent registered public accounting firm, effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 1.0

Damora Therapeutics, Inc. engaged Ernst & Young LLP as its auditor.

Action: engagement
Auditor: Ernst & Young LLP

Exact text from the filing

On April 17, 2026, the Audit Committee engaged Ernst & Young LLP (“EY US”) as the Company’s independent registered public accounting firm, effective immediately.

View on SEC.gov

Browse all auditor changes →

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-163909

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.